Dendritic cell presenting melanoma-associated antigen (null)

This refers to a therapeutic platform in which autologous dendritic cells from a patient are ex vivo loaded with melanoma-associated antigens—proteins or peptides derived from the patient’s own tumor or established melanoma cell lines. These antigen-loaded dendritic cells are then infused back into the patient, where they present the tumor-associated peptides to naïve T cells, priming a tumor-specific adaptive immune response. This strategy has shown promise in clinical studies as a personal immunotherapy for melanoma and other cancers, though the strategy is best characterized as a cellular immunotherapy rather than targeting a specific molecular receptor or protein.

Other names

Dendritic cell vaccine presenting melanoma-associated antigensDC-based melanoma vaccineMelanoma antigen-loaded autologous dendritic cellsDC-ATA (Dendritic cells loaded with autologous tumor antigens)

Ex vivo loading of patient-derived dendritic cells with autologous melanoma-associated antigens, followed by re-infusion, aiming to prime cytotoxic T lymphocytes (CD8+) and helper T cells (CD4+) against tumor antigens, thus eliciting a targeted immune response against melanoma cells